Journal article icon

Journal article

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

Abstract:

Background For women with oestrogen receptor (ER)-positive early breast cancer, treatment with tamoxifen for 5 years substantially reduces the breast cancer mortality rate throughout the first 15 years after diagnosis. We aimed to assess the further effects of continuing tamoxifen to 10 years instead of stopping at 5 years. Methods In the worldwide Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial, 12 894 women with early breast cancer who had completed 5 years of treatment with tamoxi...

Expand abstract

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
Expand authors...
Journal:
Lancet
Volume:
381
Issue:
9869
Pages:
805-816
Publication date:
2013-03-01
DOI:
EISSN:
1474-547X
ISSN:
0140-6736
Source identifiers:
389184
Pubs id:
pubs:389184
UUID:
uuid:5f79fab4-e8e9-41d7-b8f8-2d0c04460f2f
Local pid:
pubs:389184
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP